The launch comes just one day after media reports suggested that the company wants to sell its Cerenovus stroke business, the unit that makes the CereGlide system.
CereGlide 92, a next-generation .092″ catheter, features the InnerGlide 9 delivery aid. Its indication covers facilitating the insertion and guidance of interventional devices in the neurovascular system. The inner diameter catheter system allows physicians to achieve large distal access. Johnson & Johnson designed it to provide flow reduction in the M1 when inserting devices for the revascularization of patient with acute ischemic stroke.
The system’s larger lumen also provides distal support for multiple neurovascular tools when treating aneurysms and other hemorrhagic complciations. It marks the latest catheter in Johnson & Johnson MedTech’s growth catheter portfolio to integrate with stroke solutions. That includes the CereGlide 71, Prowler EX and EmboTrap III.
CereGlide 92 features design elements such as the co-packaged InnerGlide 9 delivery aid, a .092″ inner diameter, full catheter visibility with Brite-Line technology and TruCourse technology, which increases distal tip flexibility. This aids in catheter trackability. It offers large distal placement for procedural control along with full catheter visbility under fluoroscopy.
“Johnson & Johnson MedTech is continuing to innovate to help address the access challenges physicians face during mechanical thrombectomy procedures with the launch of CereGlide 92,” said Mark Dickinson, worldwide president, Neurovascular, Johnson & Johnson MedTech. “The CereGlide 92 catheter system is the latest innovation in our CereGlide and ischemic stroke suite of technologies designed to assist physicians in treating their patients and maximizing procedural outcomes, to ultimately change the trajectory of stroke.”
